JPMorgan analyst Jessica Fye downgraded Cerevel Therapeutics to Neutral from Overweight with a price target of $29, down from $40.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CERE:
- Berenberg resumes Cerevel with Hold with data readouts postponed
- Cerevel Therapeutics resumed with a Hold at Berenberg
- Cerevel Therapeutics to participate in a conference call with H.C. Wainwright
- Cerevel Therapeutics price target lowered to $26 from $28 at Mizuho
- Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference